The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | CAR T-cell therapy in B-cell malignancies
Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the dramatic and exciting approach of using CAR T-cells to treat patients with B-cell malignancies, particularly diffuse large B-cell lymphoma. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Ansell reports on-going trials looking at other targets in Hodgkin Lymphoma, including CD30 and even the microenvironment of CD30, with a goal to work against macrophages that support growth of the malignant cell. Prof. Ansell also notes the challenges in developing treatments for T-cell lymphomas, such as targeting malignant cells and not non-malignant cells. A need for more research into ways of targeting solid tumours is also implicated.
